Marcel Nold
Associate Professor
The Ritchie Centre
Hudson Institute of Medical Research
Australia
Biography
Associate Professor Marcel Nold (M.D.) is a clinician-scientist, paediatrician and neonatologist and current Fielding Foundation Fellow at Hudson Institute of Medical Research. After his graduation from medical school in 2000, he trained in paediatrics and basic immunology in Frankfurt, Germany. In 2006, he was awarded a competitive fellowship by the DFG, the German NHMRC-equivalent, to undertake a postdoctoral tenure at the laboratory of Professor Charles A. Dinarello, one of the founding fathers of cytokine biology, in Denver, CO, USA. Some of his achievements of this productive time included the description of anti-viral and angiogenic properties of interleukin (IL-)32, and the important paper on the functional differences between monocytes and macrophages (200+ citations).
Research Interest
They are now planning a clinical trial to prove the concept in babies. Because of these innovative programs, the Nolds have been awarded substantial grant funding and an international patent, and are collaborating with partners in the pharmaceutical industry.
Publications
-
Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-22.
-
Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, Skuza EM,Veldman A, Berger PJ, Nold-Petry, CA. Interleukin 1 receptor antagonist prevents murine BPD induced by perinatal inflammation and hyperoxia.PNAS 2013, 110(35):14384-89.
-
Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol, March 2015
